85908-96-9

Basic information

• Product Name: N-Boc-2-piperidone
• Synonyms: 1-(tert-Butoxycarbonyl)-2-oxopiperidine, tert-Butyl 2-oxopiperidine-1-carboxylate;Piperidin-2-one, N-BOC protected;N-(tert-Butoxycarbonyl)-5-piperidone;N-(tert-Butoxycarbonyl)-6-piperidone;N-(tert-Butoxycarbonyl)-7-piperidone;1,1-DiMethylethyl 2-Oxopiperidine-1-carboxylate;2-Oxo-1-piperidinecarboxylic Acid 1,1-DiMethylethyl Ester;2-Oxopiperidine-1-carboxylic Acid tert-Butyl Ester
• CAS NO: 85908-96-9
• Molecular Formula: C₁₀H₁₇NO₃
• Molecular Weight: 199.25
• Product Categories: Heterocycles;Intermediates;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks;Piperidine;Building Blocks;Heterocyclic Building Blocks;Piperidones
• Mol File: 85908-96-9.mol
• Article Data: 59

Chemical Properties

• Melting Point: 34-37°C
• Boiling Point: 110°C/0.1mmHg(lit.)
• Flash Point: >110 °C
• Appearance: /
• Density: 1.099 g/cm³
• Vapor Pressure: 0.000334mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Methanol
• PKA: -2.29±0.20(Predicted)
• BRN: 4674955
• CAS DataBase Reference: N-Boc-2-piperidone(CAS DataBase Reference)
• NIST Chemistry Reference: N-Boc-2-piperidone(85908-96-9)
• EPA Substance Registry System: N-Boc-2-piperidone(85908-96-9)

Safety Data

• Hazard Codes: N
• Statements: 50
• Safety Statements: 24/25-61
• RIDADR: UN 3082
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 85908-96-9(Hazardous Substances Data)

Usage

Uses

Intermediate in the preparation of various biological inhibitors.

Definition

ChEBI: Piperidin-2-one N-protected by t-Boc.

InChI:InChI=1/C10H17NO3/c1-10(2,3)14-9(13)11-7-5-4-6-8(11)12/h4-7H2,1-3H3

Upstream product

• 675-20-7 piperidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 3303-84-2 3-(tert-butyloxycarbonylamino)propionic acid 
• 69610-41-9 Boc-L-Pro-H 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 34619-03-9 tert-butyldicarbonate 
• 74-88-4 methyl iodide 
• 75844-69-8 t-butyl piperidinecarboxylate 

Downstream Products

• 27219-07-4 5-(N-tert-butyloxycarbonyl)aminopentanoic acid 
• 675-20-7 piperidin-2-one 
• 215720-35-7 [5-(4-chloro-phenyl)-5-oxo-pentyl]-carbamic acid tert-butyl ester 
• 1245646-10-9 (R)-N-tert-butoxycarbonyl-4-hydroxypiperidin-2-one 
• 1245646-10-9 (S)-N-tert-butoxycarbonyl-4-hydroxypiperidin-2-one 
• 616226-79-0 (5-oxo-5-(4-methoxyphenyl)-pentyl)-carbamic acid tert-butyl ester 
• 616226-82-5 (5-oxo-5-(4-trifluoromethylphenyl)-pentyl)-carbamic acid tert-butyl ester 
• 116437-42-4 (5-oxo-5-phenyl-pentyl)-carbamic acid tert-butyl ester 
• 128372-89-4 6-oxo-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 131667-57-7 tert-butyl 1,2,3,4-tetrahydro-1-pyridinecarboxylate 
• 154476-97-8 (E)-3-(4-methoxyphenyl)methylene-2-piperidinone 
• 138021-97-3 tert-butyl 3-allyl-4-oxopiperidine-1-carboxylate 
• 1215765-59-5 tert-butyl 2-oxo-3-(phenylselanyl)piperidine-1-carboxylate 
• 1370018-19-1 tert-butyl 3-((4-chlorophenyl)(methyl)carbamoyl)-2-oxopiperidine-1-carboxylate 

Relevant articles and documents

Design and synthesis of HDAC inhibitors to enhance the therapeutic effect of diffuse large B-cell lymphoma by improving metabolic stability and pharmacokinetic characteristics

Histone deacetylases (HDAC) are clinically validated and attractive epigenetic drug targets for human cancers. Several HDAC inhibitors have been approved for cancer treatment to date, however, clinical applications have been limited due to the poor pharmacokinetics, bioavailability, selectivity of the HDAC inhibitors and most of them need to be combined with other drugs to achieve better results. Here, we describe our efforts toward the discovery of a novel series of lactam-based derivatives as selective HDAC inhibitors. Intensive structural modifications lead to the identification of compound 24g as the most active Class I HDAC Inhibitor, along with satisfactory metabolic stability in vitro (t1/2, human = 797 min) and the desirable oral bioavailability (F = 92%). More importantly, compound 24g showed good antitumor efficacy in a TMD-8 xenograft model (TGI = 77%) without obvious toxicity. These results indicated that Class I HDAC Inhibitor could be potentially used to treat certain diffuse large B-cell lymphoma therapeutics.

N-(AZAARYL)CYCLOLACTAM-1-CARBOXAMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF

An N-(azaaryl)cyclolactam-1-carboxamide derivative having a structure of formula (I), a preparation method therefor, and a use thereof are disclosed in the application. Each substituent are defined in the specification and claims. The series of compounds of the application can be widely applied in the preparation of drugs for treating cancer, tumor, autoimmune disease, metabolic disease or metastatic disease, particularly for treating ovarian cancer, pancreatic cancer, prostate cancer, breast cancer, cervical cancer, glioblastoma, multiple myeloma, metabolic disease, neurodegenerative disease, primary tumor site metastasis or osseous metastasis cancer, and are expected to be developed into a new generation of CSF-1R inhibitor drugs.

A Unified Strategy for the Synthesis of Difluoromethyl- And Vinylfluoride-Containing Scaffolds

Here, we report a general method for the synthesis of quaternary and tertiary difluoromethylated compounds and their vinylfluoride analogues. The strategy, which relies on a two-step sequence featuring a C-selective electrophilic difluoromethylation and either a palladium-catalyzed decarboxylative protonation or a Krapcho decarboxylation, is practical, scalable, and high yielding. Considering the generality of the method and the attractive properties offered by the difluoromethyl group, this approach provides a valuable tool for late-stage functionalization and drug development.